Merck Press Releases

Published on June 6, 2016 - 12:00 GMT

KEYTRUDA® (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings from KEYNOTE-087, the phase 2 study investigating the use of KEYTRUDA® (pembrolizumab), the …

Distribution channels: Companies

Published on June 5, 2016 - 18:04 GMT

New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated findings from a study evaluating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with advanced cancers …

Distribution channels: Companies

Published on June 5, 2016 - 17:49 GMT

New Data from Phase 2 Study Evaluating KEYTRUDA® (pembrolizumab) for the Treatment of Cancers Deficient in DNA Mismatch Repair ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced updated findings from a study evaluating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with advanced cancers …

Distribution channels: Companies

Published on June 5, 2016 - 12:18 GMT

New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three separate studies evaluating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in combination …

Distribution channels: Companies

Published on June 5, 2016 - 12:04 GMT

New Data for KEYTRUDA® (pembrolizumab) in Combination with Talimogene Laherparepvec, Dabrafenib Plus Trametinib, or Low-Dose ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three separate studies evaluating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in combination …

Distribution channels: Companies

Published on June 4, 2016 - 12:09 GMT

New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from an initial proof-of-concept study of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, combined with standard …

Distribution channels: Companies

Published on June 4, 2016 - 12:09 GMT

New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data, including updated response rates, progression-free survival (PFS) and overall survival (OS) with KEYTRUDA® (pembrolizumab …

Distribution channels: Companies

Published on June 4, 2016 - 12:03 GMT

New Data Evaluating KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Non-Small Cell Lung ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced findings from an initial proof-of-concept study of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, combined with standard …

Distribution channels: Companies

Published on June 4, 2016 - 12:03 GMT

New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-010 and KEYNOTE-001 in Advanced Non-Small Cell Lung Cancer, Including Survival ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced new data, including updated response rates, progression-free survival (PFS) and overall survival (OS) with KEYTRUDA® (pembrolizumab …

Distribution channels: Companies

Published on June 1, 2016 - 21:17 GMT

Merck to Hold Investor Briefing at 2016 ASCO Annual Meeting

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Dr. Roger M. Perlmutter, president, Merck Research Laboratories, will present an overview of the company’s oncology program at the …

Distribution channels: Companies

Published on May 27, 2016 - 12:07 GMT

Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion …

Distribution channels: Companies

Published on May 24, 2016 - 18:47 GMT

Merck Announces Third-Quarter 2016 Dividend

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the third quarter of …

Distribution channels: Companies

Published on May 23, 2016 - 23:59 GMT

Merck Announces FDA Accepts Samsung Bioepis’ Biologics License Application (BLA) for SB2 (Infliximab), an Investigational ...

KENILWORTH, N.J. – Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) submitted by Samsung Bioepis Co., Ltd. …

Distribution channels: Companies

Published on May 23, 2016 - 13:06 GMT

Merck Foundation Announces the Alliance to Advance Patient-Centered Cancer Care, a $15 Million Initiative to Improve Access to ...

KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation announced today the launch of a new initiative, the Alliance to Advance Patient-Centered Cancer Care (the Alliance), to support programs aimed at improving timely access to patient-centered care and …

Distribution channels: Companies

Published on May 18, 2016 - 21:43 GMT

New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced final overall survival (OS) data from KEYNOTE-006 and new findings from KEYNOTE-001, including updated response rates, duration of …

Distribution channels: Companies

Published on May 18, 2016 - 21:29 GMT

New KEYTRUDA® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced final overall survival (OS) data from KEYNOTE-006 and new findings from KEYNOTE-001, including updated response rates, duration of …

Distribution channels: Companies

Published on May 16, 2016 - 12:19 GMT

New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data investigating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in more than 15 types of cancer …

Distribution channels: Companies

Published on May 16, 2016 - 12:12 GMT

New KEYTRUDA® (pembrolizumab) Data at 2016 ASCO Annual Meeting Includes Three-Year Overall Survival Data in Melanoma and Updated ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that new and updated data investigating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in more than 15 types of cancer …

Distribution channels: Companies

Published on May 14, 2016 - 03:24 GMT

Merck’s Investigational Once-Daily Formulation of ISENTRESS® (raltegravir) Meets Primary and Secondary Endpoints in Pivotal Phase ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced top-line results from the company’s Phase 3 pivotal trial, ONCEMRK. ONCEMRK is evaluating an investigational once-daily formulation of …

Distribution channels: Companies

Published on May 14, 2016 - 03:24 GMT

Merck Announces Second-Quarter 2016 Dividend

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.46 per share of the company’s common stock for the second quarter of …

Distribution channels: Companies

Merck Press Releases Distributed by EIN Presswire